Published in Neurology on November 08, 2005
Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology (2009) 2.00
CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology (2009) 1.85
Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology (2010) 1.66
HIV-associated neurocognitive disorder. Lancet Infect Dis (2013) 1.60
Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis (2008) 1.56
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol (2008) 1.31
Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol (2011) 1.29
Neurocognitive consequences of HIV infection in older adults: an evaluation of the "cortical" hypothesis. AIDS Behav (2011) 1.27
Factors affecting brain structure in men with HIV disease in the post-HAART era. Neuroradiology (2011) 1.27
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One (2014) 1.12
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS (2012) 1.09
HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Curr Neurol Neurosci Rep (2008) 1.04
11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol (2012) 1.00
Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J Neurol (2012) 0.99
Simvastatin protects against amyloid beta and HIV-1 Tat-induced promoter activities of inflammatory genes in brain endothelial cells. Mol Pharmacol (2008) 0.99
HIV-1 Tat contributes to Alzheimer's disease-like pathology in PSAPP mice. Int J Clin Exp Pathol (2009) 0.94
Combined effects of aging and HIV infection on semantic verbal fluency: a view of the cortical hypothesis through the lens of clustering and switching. J Clin Exp Neuropsychol (2012) 0.94
Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD). Mol Neurodegener (2011) 0.92
HIV-1 Tat interacts with and regulates the localization and processing of amyloid precursor protein. PLoS One (2013) 0.92
HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. Int J Clin Exp Pathol (2008) 0.92
HIV and aging: effects on the central nervous system. Semin Neurol (2014) 0.92
Early microstructural white matter changes in patients with HIV: a diffusion tensor imaging study. BMC Neurol (2012) 0.91
Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS One (2011) 0.90
Role of HIV in amyloid metabolism. J Neuroimmune Pharmacol (2014) 0.90
Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol (2010) 0.89
Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol (2009) 0.89
Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials (2007) 0.89
HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? Alzheimers Res Ther (2015) 0.89
HIV-associated neurocognitive disorders. J Mol Psychiatry (2014) 0.89
Elevated rates of mild cognitive impairment in HIV disease. J Neurovirol (2015) 0.89
Activation of TRPML1 clears intraneuronal Aβ in preclinical models of HIV infection. J Neurosci (2014) 0.88
The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A (2016) 0.87
Verbal memory declines more rapidly with age in HIV infected versus uninfected adults. J Clin Exp Neuropsychol (2014) 0.86
APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. BMC Neurol (2015) 0.86
APOE ε 4 allele and CSF APOE on cognition in HIV-infected subjects. J Neuroimmune Pharmacol (2010) 0.86
Potential importance of B cells in aging and aging-associated neurodegenerative diseases. Semin Immunopathol (2017) 0.83
Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders. J Neurovirol (2015) 0.82
Impact of age on markers of HIV-1 disease. Future Virol (2013) 0.82
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND). PLoS One (2014) 0.82
Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection. J Neurovirol (2011) 0.81
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease. AIDS Res Ther (2015) 0.79
Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders. Curr HIV Res (2015) 0.79
Macrophages in Progressive Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections. J Virol (2016) 0.78
Beta2-microglobulin as a diagnostic marker in cerebrospinal fluid: a follow-up study. Dis Markers (2014) 0.77
YKL-40: a candidate biomarker for simian immunodeficiency virus and human immunodeficiency virus encephalitis? Am J Pathol (2008) 0.76
The role of tau protein in HIV-associated neurocognitive disorders. Mol Neurodegener (2014) 0.76
Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Curr HIV Res (2016) 0.76
Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. J Neurovirol (2016) 0.76
Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count. J Neurovirol (2014) 0.76
HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. Am J Pathol (2017) 0.75
Fate of microglia during HIV-1 infection: From activation to senescence? Glia (2016) 0.75
Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation. J Neuroimmune Pharmacol (2016) 0.75
Neuronal Cell Death and Degeneration through Increased Nitroxidative Stress and Tau Phosphorylation in HIV-1 Transgenic Rats. PLoS One (2017) 0.75
Differentiating HIV-Associated Neurocognitive Disorders From Alzheimer's Disease: an Emerging Issue in Geriatric NeuroHIV. Curr HIV/AIDS Rep (2017) 0.75
Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV. AIDS (2017) 0.75
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Contribution of adhesion to bacterial persistence in the mouse urinary tract. Infect Immun (1983) 14.71
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Adhesion, hemagglutination, and virulence of Escherichia coli causing urinary tract infections. Infect Immun (1981) 5.24
Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect Immun (1983) 5.10
Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem (1990) 3.70
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Inhibition of experimental ascending urinary tract infection by an epithelial cell-surface receptor analogue. Nature (1982) 3.50
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol (1995) 3.23
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis (1999) 2.75
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl (2000) 2.56
Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology (2008) 2.41
Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gram-negative infection. J Immunol (1987) 2.37
Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect Immun (1984) 2.35
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res (2001) 2.19
Adhesion of Escherichia coli in urinary tract infection. Ciba Found Symp (1981) 2.15
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol (2005) 2.04
Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis (1997) 1.90
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Incidence of ROP in two consecutive Swedish population based studies. Br J Ophthalmol (2002) 1.86
CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand (2007) 1.85
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78
White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand (1991) 1.77
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol (1999) 1.68
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol (2009) 1.64
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry (2003) 1.58
Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium. Eur Respir J (2005) 1.56
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr (1999) 1.53
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology (2004) 1.47
A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods (1994) 1.46
Expression and steroid hormonal control of Muc-1 in the mouse uterus. Endocrinology (1995) 1.45
Bacterial virulence versus host resistance in the urinary tracts of mice. Infect Immun (1987) 1.45
Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol Scand (1994) 1.44
White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology (2010) 1.44
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 1.43
Bacterial adherence--a pathogenetic mechanism in urinary tract infections caused by Escherichia coli. Prog Allergy (1983) 1.42
HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy. AIDS (1997) 1.39
Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure. Eur Respir J (2005) 1.39
Cerebrospinal fluid monoamine metabolites and atmospheric pressure. Biol Psychiatry (1996) 1.39
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology (2006) 1.37
A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand (1987) 1.36
APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology (2004) 1.33
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett (1999) 1.32
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res (2005) 1.32
Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice, that affect susceptibility to gram-negative infections. J Immunol (1985) 1.32
White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry (2007) 1.31
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry (2005) 1.30
Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand (1990) 1.29
CT evaluation of coverage and congruency of the hip prior to osteotomy. Clin Orthop Relat Res (1988) 1.28
Intraarticular lesions in distal fractures of the radius in young adults. A descriptive arthroscopic study in 50 patients. J Hand Surg Br (1997) 1.28
Deep frontal and periventricular age related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls: cross sectional results from the LADIS study. J Neurol Neurosurg Psychiatry (2009) 1.28
Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 1.26
White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol (1998) 1.25
V3 sequences of paired HIV-1 isolates from blood and cerebrospinal fluid cluster according to host and show variation related to the clinical stage of disease. Virology (1993) 1.24
Structure and biology of a carcinoma-associated mucin, MUC1. Am Rev Respir Dis (1991) 1.23
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology (2007) 1.21
Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol (1998) 1.21
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) (2000) 1.20
Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci (2005) 1.20
Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res (2001) 1.19
Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr (1998) 1.18
CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology (2010) 1.18
Quinolinic acid production is related to macrophage tropic isolates of HIV-1. J Neurovirol (1995) 1.17
Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol (2001) 1.17
Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. Neurology (2012) 1.17
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging (2007) 1.17
Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res (1990) 1.15
Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand (1993) 1.15